Safety and efficacy of nonsteroidal anti-inflammatory drugs – acemetacin from the internists point of view Review article
Article Sidebar
Published:
Jun 30, 2017
Keywords:
acemetacin, pain, nonsteroidal anti-inflammatory drugs
Main Article Content
Abstract
Pain is one of the most common symptoms, regardless of age. Therefore, nonsteroidal anti-inflammatory drugs are prescribed widely. The inhibition of cyclooxygenase activity is the main mechanism of their action, the same mechanism is responsible for gastrotoxicity and nephrotoxicity as well as for rise of cardiovascular risk. It is often very hard to choose one specific drug from the hole therapeutic group – they diverge with power of action, tolerability and safety profile. This article discusses acemetacin from the internist point of view.
Article Details
How to Cite
Wełnicki , M. (2017). Safety and efficacy of nonsteroidal anti-inflammatory drugs – acemetacin from the internists point of view. Medycyna Faktow (J EBM), 10(2(35), 124-128. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2153
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Kozak-Szkopek E., Mossakowska M., Ślusarczyk P. et al.: Analiza występowania bólu przewlekłego u osób starszych w Polsce. W: Aspekty medyczne, psychologiczne, socjologiczne i ekonomiczne starzenia się w Polsce. Monografia projektu PolSenior.
2. Grosser T., Fries S., Fitzgerald G.A.: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006; 116: 4-15.
3. Abraham N.S., El-Serag H.B., Hartman C. et al.: Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment. Pharmacol. Ther. 2007; 25: 913-924.
4. Puszczewicz M.: Niesteroidowe leki przeciwzapalne. Przew. Lek. 2007; 3: 32-38.
5. Woroń J., Filipczak-Bryniarska I., Wordliczek J.: Nieopioidowe leki przeciwbólowe w farmakoterapii bólu. W: Malec-Milewska M., Woroń J.: Kompendium leczenia bólu. Wyd. 1. Medical Education, Warszawa 2012.
6. Mirowska-Guzel D., Członkowski A., Okopień B.: Farmakologia Rang i Dale. Leki przeciwzapalne i immunosupresyjne. Wyd. 2. Elsevier Urban & Partner, Toronto 2012.
7. Burke A., Smyth E., FitzGerald G.A.: Leki przeciwbólowe-przeciwgorączkowe; farmakoterapia dny moczanowej. W: Bruton L.L., Lazo J.S., Parker K.L.: Farmakoterapia Goodmana & Gilmana. Wyd. 1. Czelej, Lublin 2007.
8. Woroń J., Wordliczek J., Dobrogowski J.: Porównanie niesteroidowych leków przeciwzapalnych (NLPZ). Medycyna po Dyplomie 2011(20); 6(183): 55-63.
9. Müller P., Dammann H.G., Simon B.: Stomach tolerance of indomethacin derivatives: an endoscopic comparative study in healthy probands. Z. Rheumatol. 1986; 45(2): 68-70.
10. Lonauer G., Wirth W.: Controlled double blind study on the effectiveness and adverse effects of acemetacin and indomethacin in the treatment of psoriatic arthritis. Arzneimittelforschung. 1980; 30(8A): 1440-1444.
11. Heiter A., Tausch G., Eberl R.: Controlled double blind comparison of acemetacin to indomethacin in patients with chronic polyarthritis. Arzneimittelforschung. 1980; 30(8A): 1427-1433.
12. Kronhagel R.: Clinical results of a double blind study with the new antirheumatic agent acemetacin. Arzneimittelforschung. 1980; 30(8A): 1445-1448.
13. Rechziegler H., Zündorf P.: Acemetacin in the treatment of rheumatic diseases: an open, multi-centre trial. Curr. Med. Res. Opin. 1985; 9(10): 701-707.
14. Müller P., Dammann H.G., Langer M. et al.: Ranitidine ameliorates acemetacin and indomethacin-induced changes of the gastroduodenal mucosa, without modifying the pharmacokinetic behavior of both antirheumatic drugs. Z. Gastroenterol. 1989; 27(2): 83-86.
15. Chou C.T., Tsai Y.Y.: A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int. J. Clin. Pharmacol. Res. 2002; 22(1): 1-6.
16. Leeb B.F., Bucsi L., Keszthelyi B. et al.: Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib. Orthopade 2004; 33(9): 1032-1041.
17. Uncu H.: A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis. Phlebology 2009; 24(2): 56-60.
18. Nissen S.E., Yeomans N.D, Solomon D.H. et al.: Cardiovascular Safety if Celecoxib, Naproxen or ibuprofen for Arthritis. N. Engl. J. Med. 2016. DOI: 10.1056/NEJMoa1611593
2. Grosser T., Fries S., Fitzgerald G.A.: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006; 116: 4-15.
3. Abraham N.S., El-Serag H.B., Hartman C. et al.: Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment. Pharmacol. Ther. 2007; 25: 913-924.
4. Puszczewicz M.: Niesteroidowe leki przeciwzapalne. Przew. Lek. 2007; 3: 32-38.
5. Woroń J., Filipczak-Bryniarska I., Wordliczek J.: Nieopioidowe leki przeciwbólowe w farmakoterapii bólu. W: Malec-Milewska M., Woroń J.: Kompendium leczenia bólu. Wyd. 1. Medical Education, Warszawa 2012.
6. Mirowska-Guzel D., Członkowski A., Okopień B.: Farmakologia Rang i Dale. Leki przeciwzapalne i immunosupresyjne. Wyd. 2. Elsevier Urban & Partner, Toronto 2012.
7. Burke A., Smyth E., FitzGerald G.A.: Leki przeciwbólowe-przeciwgorączkowe; farmakoterapia dny moczanowej. W: Bruton L.L., Lazo J.S., Parker K.L.: Farmakoterapia Goodmana & Gilmana. Wyd. 1. Czelej, Lublin 2007.
8. Woroń J., Wordliczek J., Dobrogowski J.: Porównanie niesteroidowych leków przeciwzapalnych (NLPZ). Medycyna po Dyplomie 2011(20); 6(183): 55-63.
9. Müller P., Dammann H.G., Simon B.: Stomach tolerance of indomethacin derivatives: an endoscopic comparative study in healthy probands. Z. Rheumatol. 1986; 45(2): 68-70.
10. Lonauer G., Wirth W.: Controlled double blind study on the effectiveness and adverse effects of acemetacin and indomethacin in the treatment of psoriatic arthritis. Arzneimittelforschung. 1980; 30(8A): 1440-1444.
11. Heiter A., Tausch G., Eberl R.: Controlled double blind comparison of acemetacin to indomethacin in patients with chronic polyarthritis. Arzneimittelforschung. 1980; 30(8A): 1427-1433.
12. Kronhagel R.: Clinical results of a double blind study with the new antirheumatic agent acemetacin. Arzneimittelforschung. 1980; 30(8A): 1445-1448.
13. Rechziegler H., Zündorf P.: Acemetacin in the treatment of rheumatic diseases: an open, multi-centre trial. Curr. Med. Res. Opin. 1985; 9(10): 701-707.
14. Müller P., Dammann H.G., Langer M. et al.: Ranitidine ameliorates acemetacin and indomethacin-induced changes of the gastroduodenal mucosa, without modifying the pharmacokinetic behavior of both antirheumatic drugs. Z. Gastroenterol. 1989; 27(2): 83-86.
15. Chou C.T., Tsai Y.Y.: A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int. J. Clin. Pharmacol. Res. 2002; 22(1): 1-6.
16. Leeb B.F., Bucsi L., Keszthelyi B. et al.: Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib. Orthopade 2004; 33(9): 1032-1041.
17. Uncu H.: A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis. Phlebology 2009; 24(2): 56-60.
18. Nissen S.E., Yeomans N.D, Solomon D.H. et al.: Cardiovascular Safety if Celecoxib, Naproxen or ibuprofen for Arthritis. N. Engl. J. Med. 2016. DOI: 10.1056/NEJMoa1611593